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Abstract

Objectives The aim of this study was to determine the frequency and severity of adverse events (AEs) reported
from use of an adjuvanted whole-cell autologous cancer vaccine in cats with solid tumors under field conditions.
Methods The case accession database at Torigen Pharmaceuticals was searched to identify client-owned cats that
underwent biopsy or surgical resection of their primary tumor, had histologic confirmation of neoplasia and received
at least one subcutaneous dose of an adjuvanted whole-cell autologous cancer vaccine. Records were reviewed
for any reported AEs.
Results In total, 117 cats met the inclusion criteria and received 422 doses of autologous cancer vaccine. Six
(5.1%) cats had seven reported AEs, with the majority of these (85.7%) being characterized as grade 1 or 2 (mild)
and resolving without medical intervention.
Conclusions and relevance AEs were infrequent in cats treated with an adjuvanted whole-cell autologous
cancer vaccine under typical field use conditions. This form of active cancer immunotherapy appears to be well
tolerated by cats and may represent a treatment option for owners who are concerned about AEs associated
with chemotherapy or radiotherapy. Additional studies are warranted to determine the efficacy of this form of
individualized immunotherapy in cats with solid tumors.
Keywords: Autologous cancer vaccine; cancer; cancer immunotherapy; safety
Accepted: 17 June 2021

Introduction
Since the 1960s there has been a keen interest in how
to direct a patient’s immune system to fight cancer.
Autologous vaccines represent one of the earliest forms of
immunotherapy studied, beginning with a rabbit model
of viral-induced carcinoma.1 Autologous cancer vaccines
(ACVs) represent a form of active immunotherapy in
which antigenic material is derived from the patient’s
own tumor.2 After ex vivo processing, tumor cells are
returned to the patient with the goal of stimulating an
immune response against multiple tumor antigens unique
to the individual. A successful immune response involves
cytotoxic T cells capable of recognizing tumor-associated
antigens (TAAs) and tumor-specific antigens that may be
abundantly expressed or unique to the patient.3 Various
methods of tumor processing have been used to create
ACVs, including whole-cell vaccines, tumor-cell lysates,

isolation of specific intracellular components (eg, heat
shock proteins [HSPs]) and transfection of cells to induce
novel antigen presentation.4 Before being administered to
the patient, the cancer cells are inactivated using chemical treatment, cell lysis or irradiation.5–7 Subcutaneous
(SC), intramuscular (IM), intraperitoneal and intradermal
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routes of administration of ACVs have been described in
dogs.5,6,8,9 To date, ACVs have not been evaluated in cats.
As early as 1964 it was recognized that ACVs were
capable of inducing a humoral immune response in
human patients with terminal cancer.10 The method of
tumor processing was also discovered to affect the TAAs
available for presentation to the immune system, and
various strategies were studied to chemically or enzymatically dissociate tumor cells to try and preserve the
most TAAs.11 Early development of ACVs was slow given
the rudimentary understanding of the immune system, as
well as the paucity of available reagents and instrumentation. Through the late twentieth century, studies of ACVs
were conducted in people with melanoma, colorectal carcinoma, head and neck squamous cell carcinoma (SCC),
non-small-cell lung cancer and renal cell carcinoma,
among others.12–18 The interest in ACVs has continued
over the past 50 years in human oncology, with multiple
ongoing human clinical trials describing some form of
ACV listed on the ClinicalTrials.gov website.19
The development of ACVs in veterinary oncology
has progressed more slowly than in human medicine.
This is owing, in part, to the lack of validated reagents
for studying the immune system in companion animals.
As a result, there are only a handful of canine studies
describing ACVs in the veterinary literature, including
vaccines created from irradiated cancer cells transfected
with human granulocyte–macrophage colony-stimulating
factor, cancer cells transfected with the gene encoding
Emm55, a Streptococcus pyogenes serotyping antigen, a
whole-cell vaccine prepared using enzymatic cell dissociation and an autologous vaccine consisting of HSPs
isolated from the patient’s tumor with a hydroxylapatite
ceramic powder adjuvant.9,20–22
Similarly, there are limited published safety data
regarding ACVs in veterinary medicine. There were no
significant adverse events (AEs) described in the studies discussed above.9,20–22 Additional evidence that this
form of immunotherapy is safe for dogs comes from two
recently published studies. The first report described 150
IM injections of an adjuvanted autologous tumor lysate
preparation to a group of 28 cancer-bearing dogs.6 No significant AEs were reported. The second report described
the AEs in 93 cancer-bearing dogs treated with an adjuvanted whole-cell ACV, which is the same ACV used
in the present feline study.5 Approximately 10% of the
treated dogs developed mild AEs after vaccine administration. All of the described AEs were characterized as
grade 1 (mild) on the Veterinary Comparative Oncology
Group – Common Terminology Criteria for Adverse
Events (VCOG-CTCAE) scale,23 and included redness
or discomfort at the injection site, mild lethargy, transient decrease in appetite or low-grade fever. None of
the described AEs required medical intervention and all
resolved spontaneously.
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To date, there have been no published reports of the
use of active cancer immunotherapy with an ACV in cats.
The purpose of this study was to determine the frequency
and severity of AEs in cats treated with an adjuvanted
whole-cell ACV that has been previously evaluated
in dogs.5

Materials and methods
Autologous cancer vaccine protocol
After surgical excision, unfixed tumor tissue was placed
into an empty, sterile container and shipped overnight
on cold packs to the commercial laboratory (Torigen
Pharmaceuticals, Farmington, CT, USA) for preparation of the ACV. The vaccine preparation has been
described elsewhere.5 Briefly, the tumor tissue was
mechanically dissociated into a uniform cell suspension,
cells were inactivated with 2.5% glutaraldehyde and
eventually combined with a protein matrix immunomodulator adjuvant (MIM-SIS; Cook Biotech). The
final vaccine product was placed into a sterile vial and
shipped overnight on cold packs to the submitting veterinarian for administration to the cat. Veterinarians
were instructed to give 1 ml of the vaccine SC once every
7 days for three total doses. The attending veterinarian
was further instructed to monitor the cat for acute AEs for
30 mins after each of the three injections. At hospital discharge, cat owners were also informed of possible vaccine
reactions and instructed to report any observed abnormalities immediately upon their occurrence. Written
owner informed consent was obtained before the vaccine was produced and administered as required by the
United States Department of Agriculture for unlicensed
biologics.
Case selection
The case accession database at Torigen Pharmaceuticals
was queried to identify cats treated with the adjuvanted
whole-cell ACV between November 2015 and November
2020. Cats were eligible for inclusion in this study if they
had a histopathologic or cytologic diagnosis of cancer
and received at least one dose of the vaccine. Cats were
excluded from study if they had a histologic or cytologic
diagnosis of a non-cancerous process, did not receive at
least one dose of the adjuvanted whole-cell ACV, received
adjuvant chemotherapy or radiation therapy concurrent
with ACV treatment or had incomplete case information.
Histopathologic and cytologic diagnoses were reported
by board-certified veterinary pathologists via commercial
laboratory services. Patient data collected included signalment, body weight, histology or cytology results and
reported AEs following ACV administration. Details on
AEs were collected from telephone or email contact with
the cat owners and submitting veterinarians, or through
a survey tool sent at regular intervals to each submitting
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veterinarian. Follow-up information for each cat with a
reported AE was obtained through direct communication with the submitting veterinarian and medical records
were requested for affected cats. An AE was considered to
be any observation in treated cats that was unfavorable,
unintended and occurred after the use of the investigational veterinary product, whether or not it was considered to be product-related.24 AEs were classified based on
the VCOG-CTCAE.23
Summary statistics were generated using commercial
software (XLSTAT Life Science 2020; Addinsoft). Results
are reported as mean ± SD unless otherwise noted.
Informed consent
Informed written consent was obtained from the owner
or legal custodian of all animals described in this work
for the procedures undertaken regarding the clinical use
of the investigational, commercially available, autologous cancer vaccine as required by the United States
Department of Agriculture (USDA) for unlicensed veterinary biologics.

Results
Study population
There were 193 feline cases identified in the database. Of
these cats, 61 (31.6%) did not receive any vaccine dose as a
result of the owners or attending veterinarians opting for
other treatment options, a non-cancerous diagnosis or the
death of the patient before the vaccine could be administered. One of these patients that was coded as a Bengal cat
was actually a Bengal tiger and therefore excluded from
study. An additional 15 (7.8%) cats that received at least
one dose of the vaccine were excluded from the study
owing to concurrent use of chemotherapy (n = 10), no
pathology report provided by the attending veterinarian
(n = 4) or non-cancerous process (n = 1).
During the 5-year study period, 438 doses of the adjuvanted whole-cell ACV were administered to 117 cats that
met the inclusion criteria. The mean number of vaccine
doses administered per cat was 3.7 ± 3.29 (median 3.0;
range 1–36). Eighteen (15.4%) cats were treated with >1
course (ie, more than 3 doses) of the adjuvanted wholecell ACV during the study period, owing to cancer recurrence or the development of a new malignancy. Sixteen
cats received six doses of the adjuvanted whole-cell ACV,
one cat received 12 doses and one cat received 36 doses
over the course of 4 years during the study period. The
male:female ratio was approximately 1:1, and the majority (71.8%) of cats were described as domestic shorthairs.
Summary data are presented in Table 1.
Tumor specimens were submitted from cats in 26 different states, with the largest proportion of cases coming
from Connecticut and Washington (Figure 1). General
practitioners submitted 76 (65.0%) cases, and 41 (35.0%)
cases were submitted by specialists (surgeons and
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Table 1 Summary data from 117 cancer-bearing cats
treated with surgery and an adjuvanted whole-cell
autologous cancer vaccine (ACV)
Variable
Age (years)
Range
Weight (kg)
Range
Sex
Male
Female
Reproductive status
Neutered
Intact
Breed
Domestic shorthair
Domestic longhair
Maine Coon
Other breeds
Cancer origin
Epithelial
Mesenchymal
Round cell
Doses of Torigen ACV administered
Doses per cat
Range
AEs
Affected cats
Doses associated with AEs
Doses associated with serious AEs

11.1 ± 3.33
3.0–19.9
5.1 ± 1.70
1.8–13.4
58 (49.6)
59 (50.4)
114 (97.4)
3 (2.6)
84 (71.8)
13 (11.1)
4 (3.4)
16 (13.7)
48 (41.0)
59 (50.4)
10 (8.5)
438
3.7 ± 3.29
1–36
7
6 (5.1)
6 (1.4)
1 (0.2)

Data are n (%) or mean ± SD
AEs = adverse events

medical oncologists). There were 48 (41.0%) epithelial
tumors, 59 (50.4%) mesenchymal tumors and 10 (8.5%)
discrete round-cell tumors. The most commonly submitted epithelial tumors were mammary gland carcinomas
(n = 19 [39.6%]) and SCCs (n = 7 [14.6%]). Soft tissue sarcomas (n = 53 [86.9%]), of which 18 were described as
injection-site sarcomas, represented the most commonly
submitted mesenchymal tumor. Lymphoma was the most
frequent round-cell tumor submission (n = 5 [50%]).
AEs
There were seven AEs reported in six (5.1%) cats, which
were associated with six (1.4%) doses of the novel adjuvanted whole-cell ACV. The most common AE was
lethargy, reported in four cats. Of the reported AEs, six
(85.7%) were characterized as mild or moderate (grade
1 or 2), and there was only one severe (grade 5) AE
reported. AEs were reported after the first adjuvanted
whole-cell ACV dose in three (42.9%) cats, after the second dose in two (28.6%) cats and after the third dose in
one (14.3%) cat. One cat with an oral SCC had two AEs
(lethargy and anorexia) reported after the second dose
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Figure 1 Geographic distribution of 117 cats treated with an adjuvanted whole-cell autologous cancer between November
2015 and November 2020

of the vaccine; there were no reported AEs with the first
or third doses, nor with three additional doses given 2
months after the initial series owing to local tumor progression. The remaining 15 cats treated with more than
three doses of the adjuvanted whole-cell ACV had no
reported AEs. Regarding the attribution of reported AEs
to the adjuvanted whole-cell ACV, one (14.3%) was classified as unrelated, two (28.6%) were classified as unlikely,
two (28.6%) were classified as possible and two (28.6%)
were classified as probable.
The AE that was classified as unrelated, which was
also the only severe AE, was reported in a cat with metastatic pulmonary carcinoma. The cat died at home 3 days
after the first dose of the vaccine. Necropsy revealed pleural effusion, carcinomatosis and effacement of pulmonary tissue by neoplastic cell, making cancer the probable
cause of death. For the two AEs considered unlikely to
be related to the novel adjuvanted whole-cell ACV, the
first was fever following the first dose of vaccine in a cat
with laryngeal lymphoma. The cat owner was keeping
the cat on an electric heating pad at the time the fever was
reported, and the cat also suffered second-degree burns
on the ventral body wall. The elevated body temperature
was thought to be a result of exposure to the heating pad.
The second AE unlikely to be related to the vaccine was
lethargy, which was reported after the third dose in a
cat with mammary carcinoma. An infection was concurrently diagnosed at the mastectomy incision site, which
was likely the cause of the observed lethargy.
The two AEs that were classified as possibly related
to the vaccine were reported in the cat with oral SCC

described above. The two AEs that were classified
as probable were reported in a cat with osteosarcoma
shortly after the second vaccine dose, and in a cat with
an injection-site swelling several hours after the first dose.

Discussion
For consistency with previously published safety and efficacy data in dogs treated with this ACV,5,25 cats described
herein were also given a series of three SC injections
spaced 1 week apart. The most effective interval for ACV
administration remains unknown. Rodent data on the
effect of dosing interval on efficacy are limited; studies
that are available often do not detail which intervals are
best to produce an immune response. A recent study in
mice revealed that three doses of an autologous vaccine
generated a superior immune response and better tumor
control, compared with mice treated with either one or
five doses.26 Given the heterogeneity of ACV products,
and a lack of conclusive mouse model data, it is difficult
to extrapolate mouse model results to an effective dosing
scheme in feline patients. In a study of an ACV given IM
to dogs, no significant difference in AE rates was found
between dogs receiving four weekly administrations
and a group treated with four doses given at 4-week
intervals.6 Presently, there is no consensus on the optimal
dosing interval for ACVs in humans, in part, owing to a
comparative lack of data on clinically successful autologous vaccines relative to infectious disease vaccines.27
The population of cats described herein was geographically diverse, and the observed middle age of the
affected cats was similar to previous reports.28,29 The
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predominance of mesenchymal tumors within this population is different than the majority of epithelial tumors
described in a review of the Swiss Feline Cancer Registry.29
This may reflect the smaller population size herein, or be
a result of the different genetic make-up of cats in the USA
vs Switzerland. This could also represent case selection
bias by the submitting veterinarians, if cat owners opt
out of postoperative radiation therapy for managing soft
tissue sarcomas; round-cell tumors and carcinomas have
a wider array of available adjuvant treatment options.
Likewise, a higher risk of female cats developing cancer
was observed in the Swiss Feline Cancer Registry;28 that
finding was not replicated here. Unfortunately, there are
no contemporary feline cancer registries in the USA to
allow for comparison of breed distribution.
The cancer-bearing cats treated with immunotherapy
in this study all tolerated the novel adjuvanted wholecell ACV well, with a few, mild AEs described. The AE
rate in the group of cats described herein was even lower
than previously reported in 93 dogs (11.8%),5 as well as
a group of 28 horses (14.3% [MD Lucroy, unpublished
data]) treated with the same ACV.
Given the retrospective nature of this study, and the
potential for veterinarians or cat owners to not report
observed AEs, it is possible that the observed AE rate
could be lower than the actual rate. However, ACVs
detailed in the human literature have a consistently
reported low rate of AEs. In a human study of an ACV
modified genetically with tag7/PGRP-S, none of the
patients demonstrated any clinical significant signs of
toxicity.30 Additional studies of ACVs in humans with
solid tumors have reported a similar lack of AEs or clinically significant events, with the worst AEs being infrequent and limited to grade 1/2 AEs.31,32 Moreover, the
adjuvant (MIM-SIS) used in the ACV studied here is a
non-irritating adjuvant that has a very low incidence
of AEs, while also being capable of producing a robust
immune response against co-administered antigens.33,34
Based on the reported safety of autologous cancer vaccines among various species, and the properties of MIMSIS, the low AE rate reported in this population of cats
is likely representative of what could be expected with
more widespread use.
Only one of the 18 cats that received more than three
doses of the novel adjuvanted whole-cell ACV during
the study period was reported to have an AE. This was
an episode of mild lethargy following the second vaccine dose. No AEs were reported following the other five
doses. Sixteen cats received six doses of the novel adjuvanted whole-cell ACV, one cat received 12 doses and
one cat received 36 doses during the 5-year study period,
demonstrating that repeated exposure over time does not
appear to increase the risk of an AE.
Although chemotherapy is a commonly used adjuvant
treatment after cancer surgery, many cat owners are concerned about AEs associated with chemotherapy. A study
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of pet owners revealed that 58% would not pursue chemotherapy citing concerns about the risk for AEs.35 This is
not an unfounded fear. Neutropenia is most commonly
the dose-limiting AE, and vomiting and diarrhea are commonly reported, with cats being particularly sensitive to
diminished appetite and weight loss.36 In a population
of 70 cats treated with doxorubicin, alone or as part of
a combination chemotherapy protocol, 34% had at least
one episode of neutropenia, 44% were anemic and 29%
developed acute kidney injury.37 Appetite decrease, vomiting and diarrhea were also reported in 13%, 16% and
7% of instances, respectively, where recorded. Similarly,
a retrospective study of cats with mast cell cancers treated
with oral toceranib phosphate (Palladia; Zoetis) had
a reported AE rate of 60%, including gastrointestinal
and hematologic events, which necessitated a break in
treatment.38 Therefore, the adjuvanted whole-cell ACV
used in the present study may represent an appealing
option for cat owners concerned about potential risks
associated with chemotherapy. Until efficacy data regarding this ACV are published, it will be impossible for veterinarians and cat owners to assess the risk:benefit ratio
when making treatment decisions.
The strengths of the study include the large number
of cats described herein that received >400 doses of the
ACV, and that the reported observations represent the
experience from typical use in the field. These results
are valuable for veterinarians when discussing cancer
treatments with cat owners. Including owner-reported
AEs provides additional information not readily available from a medical record review. In human medicine,
patient reports of AEs have been shown to be a credible
source of information for care-related AEs.39 A limitation
of this study is the retrospective nature of case reviews.
Given the low rate of AEs described in this population
of 117 cats under field conditions, and the previous report
describing a low rate of AEs in a population of 93 similarly treated dogs at a single surgery practice,5 this adjuvanted whole-cell ACV appears to be a comparatively
safe cancer treatment. Further studies are warranted to
determine the efficacy of this form of active immunotherapy in cancer-bearing cats.

Conclusions
AEs were infrequent in the population of cats treated with
an adjuvanted whole-cell ACV. This form of active cancer immunotherapy appears to be well tolerated by cats
and may represent an alternative treatment for owners
who are concerned about AEs associated with chemotherapy or radiotherapy. Additional studies are warranted
to determine the efficacy of this form of individualized
immunotherapy in cats with solid tumors.
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